A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of NPT088 in Patients With Probable Alzheimer's Disease

Trial Profile

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of NPT088 in Patients With Probable Alzheimer's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs NPT 088 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Proclara Biosciences
  • Most Recent Events

    • 17 Jul 2017 According to a Proclara Biosciences media release, company expects to release topline efficacy data in the summer of 2018.
    • 17 Jul 2017 Initial interim results published in a Proclara Biosciences media release.
    • 17 Jul 2017 According to a Proclara Biosciences media release, company will continue its ongoing Phase 1b trial of NPT088 in patients with Alzheimers disease following the positive recommendation of the trials independent data monitoring committee. This recommendation is based on a review of interim safety data compiled from the trial to date.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top